Ranbaxy Suspends API Shipments from Two Plants in India - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ranbaxy Suspends API Shipments from Two Plants in India

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 3

Ranbaxy Laboratories has announced that it has temporarily suspended shipments of active pharmaceutical ingredients (APIs) produced at its Toansa and Dewas plants in India.

On Jan. 24, the company announced that API shipments from the Toansa plant to the United States were suspended. The company says it has now voluntarily suspended all API shipments from both the Toansa and Dewas plants in order to allow for further evaluation and inspection of manufacturing processes and quality control systems. The temporarily suspended shipments will be resumed once the processes and controls at these facilities are reconfirmed based on internal evaluations and inspections.

Ranbaxy has also announced that a Quality and Integrity Committee, established as a sub-committee of the Ranbaxy Corporate Board of Directors in order to improve corporate governance, has been in operation from early February 2014. 

In a statement, parent company Daiichi Sankyo issued an apology to all its stakeholders “for the inconvenience caused by the further suspension of API shipments this time. As Ranbaxy is one of our most important affiliates in the Group, Daiichi Sankyo is committed to continuing to offer full support for Ranbaxy to improve quality standards,” the statement read.

Source: Daiichi Sankyo

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here